Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Creatine ascorbate is a stable salt compound consisting of creatine and ascorbic acid (Vitamin C). It is primarily investigated for its potential to treat creatine transporter deficiency (CTD), a condition where the primary creatine transporter (SLC6A8) is non-functional. By linking creatine to ascorbate, the compound is hypothesized to enter cells via sodium-dependent vitamin C transporters (SVCT1 and SVCT2), thereby bypassing the defective creatine transporter. Research indicates it can delay synaptic failure during anoxia and may serve as an adjunctive therapy in cancer, specifically enhancing the effects of methylglyoxal in sarcoma models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on creatine ascorbate.